Data / Form D filings / Allyx Therapeutics, Inc.
Allyx Therapeutics, Inc.: Form D filing
Allyx Therapeutics, Inc., a biotechnology company in New Haven, CT, filed a Form D with the SEC in 2026. The latest, on October 21, 2026, reports $27.9 million sold of a $30 million offering to 33 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 555 Long Wharf Drive Floor 11, New Haven, CT, 06511
- Phone
- (908) 432-2845
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1865257
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 21 | Amendment | $29,999,999 | $27,927,729 | $2,072,270 | 33 | May 4 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Stephen Bloch | Executive Officer, Director | |
| Stephen Strittmatter | Director | |
| Paul Fonteyne | Director | |
| Gregory P Ho | Director | |
| Robert A Bettigole | Director | |
| Timothy Siegert | Executive Officer | |
| Kevin L. Rakin | Director |
Every Form D from the week of Oct 19 · All recent filings in Connecticut · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Allyx Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.